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To improve efficacy of photodynamic therapy (PDT) with intravenously administered 5-aminolaevulinic acid (ALA) fractionating the
light dose or reducing the light intensity may be a possibility. Therefore, Syrian Golden hamsters were fitted with dorsal skinfold
chambers containing an amelanotic melanoma (n¼26). PDT was performed (100mWcm
 2, 100Jcm
 2, continuously or
fractionated, and 25mWcm
 2, 100Jcm
 2; continuously or fractionated) using an incoherent light source following i.v. application of
ALA. Following fractionated irradiation, the light was paused after 20Jcm
 2 for 15min. Prior to and up to 24h after PDT tissue, pO2
was measured using luminescence lifetime imaging. The efficacy was evaluated by measuring the tumour volume of amelanotic
melanoma cells grown subcutaneously in the back of Syrian Golden hamsters (n¼36). Only high-dose PDT resulted in a significant
decrease of pO2. Irrespective of the mode of irradiation only high-dose PDT induced complete remission of all tumours (13 out of
13). It could be shown that low-dose PDT failed to induce a significant decrease of pO2. No significant effect of fractionated
irradiation was shown regarding the therapeutic efficacy 28 days after PDT. Thus performing a fractionated PDT with ALA or
reducing the light intensity seems not to be successful in clinical PDT according to the present data.
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Photodynamic therapy (PDT) involves the generation of reactive
oxygen species after activation of a photosensitiser by light (Pass,
1993; van Hillegersberg et al, 1994; Dougherty et al, 1998). Since
the only clinically approved systemic photosensitiser, Photofrin
s,
causes generalised cutaneous photosensitivity up to 4–6 weeks
following PDT, 5-aminolaevulinic acid (ALA) has raised hope as a
promising photosensitiser for PDT (Peng et al, 1997). The
endogenous photosensitiser ALA is a haem precursor and induces
the synthesis of porphyrins (protoporphyrin IX, PpIX) in
mitochondria-containing cells (Williams, 1990). A selectivity of
ALA-induced porphyrins is described in neoplastic tissue (Abels
et al, 1994; Ackermann et al, 1998; Langer et al, 1999) as well as in
malignant cells (Rittenhouse-Diakun et al, 1995) and provides the
basis for clinical use of ALA-based photodynamic therapy (Mlkvy
et al, 1995) and diagnosis (Kriegmair et al, 1995). ALA is water
soluble and can therefore be administered either systemically
(Grant et al, 1993) or topically (Szeimies et al, 1994).
However, PDT with intravenously administered ALA failed to be
as successful as PDT with Photofrin
s in an amelanotic melanoma
(Abels et al, 1997a). To improve efficacy of ALA–PDT fractionat-
ing the light dose or reducing the light intensity might be a
possibility (Gibson et al, 1990; Messmann et al, 1995; de Bruijn
et al, 1999; Iinuma et al, 1999). Splitting the light dose into
fractions by pausing the light source for a certain time is supposed
to enable reoxygenation of the irradiated tissue and may increase
the generation of singlet oxygen thus enhancing PDT (Hua et al,
1995; Robinson et al, 2000; Pogue et al, 2001). In addition, new
PpIX might be formed during the irradiation break further
contributing to the generation of reactive oxygen species during
the second irradiation turn (de Bruijn et al, 1999; Robinson et al,
2000). A low-dose PDT is supposed to result in a slower oxygen
consumption and therefore allows oxygen to be continuously
supplied compared with high-dose PDT (Hua et al, 1995; Robinson
et al, 2000; Pogue et al, 2001). Therefore, the oxygen concentration,
for example, partial oxygen pressure (pO2), in the tissue is critical
and the measurement of tissue oxygenation is of great importance.
It is well known that the pO2 in normal tissue is different from the
pO2 in tumour tissue. While in normal tissue, the median pO2-
values range from 24 to 66mmHg, the value in the respective
malignant tissue is p20mmHg (Vaupel et al, 1989).
In this study, the pO2 in tumour and surrounding tissue was
measured to evaluate the therapeutic effect of different dosimetric
protocols for ALA–PDT in vivo. The technique of measuring the
tissue pO2 by planar optical sensors and luminescence lifetime
imaging (Liebsch et al, 2000, 2001) allows a spatially highly
resolved mapping of two-dimensional pO2-distribution within the
chamber tissue in a noninvasive way. In addition, the pO2-
measurements were then correlated with tumour growth after PDT
with the respective dosimetric protocol.
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sMATERIALS AND METHODS
Animal and tumour model
For experiments male Syrian Golden hamsters of 30–40g body
weight (b.w.) (Breeder: Fa. Harlan-Winkelmann GmbH, Borchen,
Germany) and cells of the amelanotic hamster melanoma (A-Mel-
3) were used (Fortner et al, 1961). The animals were housed in
single cages and had free access to food and water.
For the pO2-measurements, the animals were fitted with
titanium dorsal skinfold chambers obtained from the Institute
for Surgical Research, Munich, Germany (n¼26). They tolerated
the chambers well and showed no signs of discomfort. Amelanotic
melanoma cells (A-Mel-3) (Fortner et al, 1961) were implanted
(approximately 2 10
5 A-Mel-3 cells in suspension) in the dorsal
skinfold chamber 48h after surgical preparation of the chambers
exhibiting an intact microcirculation (for details see, Endrich et al,
1980). At 5 days after tumour cell implantation, permanent
indwelling catheters (PE-10, 0.4mm i.d., Portex, Hythe, UK) were
inserted into the right carotid artery and right external jugular vein
under ketamine/xylazine anesthesia (100 and 8mg kg
 1 b.w. i.p.).
To evaluate the impact of the different irradiation protocols on
tumour growth 5 10
6 amelanotic melanoma cells were implanted
subcutaneously in the shaved and chemically depilated (Pilca med,
Olivin, Hamburg, Germany) dorsal skin of the hamsters (n¼36)
under ketamine/xylazine anaesthesia (100 and 8mg kg
 1 b.w. i.p.)
(Dellian et al, 1995; Abels et al, 1997a,b). The take rate of the
tumours following implantation was 100%. After 4 days of growth,
the tumours had grown to a mean volume of approximately
100mm
3 (mean tumour volume, 10077.5mm
3). Permanent
indwelling catheters (PE-10, 0.4mm i.d., Portex, Hythe, UK) were
inserted into right external jugular vein under ketamine/xylazine
anaesthesia (100 and 8mgkg
 1 b.w. i.p.) and removed after ALA
application.
All experiments have been carried out with ethical committee
approval and meet the standards required by the UKCCCR
guidelines (Workman et al, 1988). In addition, each procedure
was approved by the regional authorities according to the German
animal care regulations, which are in accordance with the
international guidelines of animal care and use in scientific
experiments (AZ 621 2531.1-28/00).
Preparation and administration of ALA
5-Aminolaevulinic acid as a hydrochloride salt (MW 168) was
obtained from Merck (Darmstadt, Germany), dissolved in NaCl
(pH 6.5) at a concentration of 100mgml
 1 and used immediately.
5-Aminolaevulinic acid was administered intravenously in a dose
of 500mgkg
 1 b.w. according to previous experiments (Abels et al,
1994, 1997a; Szeimies et al, 1995). The conscious animals did not
show any signs of discomfort during injection of the ALA-solution
as previously reported by Edwards et al (1984).
pO2-Measurement
The pO2-measurement was performed using luminescence lifetime
imaging of a luminescent oxygen indicator, which is immobilised
in an oxygen permeable sensor foil (for details see, Liebsch et al,
2000, 2001). The indicator is capable of translating the respective
oxygen partial pressure into a light signal. The optical pO2-sensor
foil (platinum(II)-octaethyl-porphyrin in polystyrene) was cali-
brated in vitro and attached to the cover glass of the chamber
preparation in direct contact with the surface of the chamber
tissue. Thus, the pO2 of the tissue surface can be measured at any
time noninvasively. PDT can be performed through the transpar-
ent sensor foil because irradiation does not damage the
luminescent oxygen sensor (data not shown). A transillumination
image can be generated and overlaid with the respective pO2-
image.
The hamsters were fixed in a Perspex tube placed on a
motorised, computer-controlled stage (Spindler & Hoyer GmbH,
Go ¨ttingen, Germany). The temperature of the dorsal skinfold
chamber was kept constant by a custom-made water bath at 291C.
For intravital microscopy (IVM), a Zeiss Axiotech Vario 100 HD
microscope was modified for time-resolved imaging of lumines-
cent sensor foils. A fast gateable CCD-camera (SensiMod, PCO,
Kehlheim, Germany) and a pulsed light source were mounted to
the microscope. Green excitation light (535nm) was reflected by a
dichroic mirror (Deep Orange, O590, Balzers) to the pO2-sensor
foil of the observation chamber of the dorsal skinfold chamber.
The sensor luminescence was optically filtered with a long-pass
filter (RG630, Fa. Schott, Mainz, Germany) and detected via rapid
lifetime determination (RLD) (for details see, Liebsch et al, 2000,
2001).
Prior to PDT, a transillumination image and a pO2-image were
generated. At 15min, 1, 2 and 24h after PDT and, in case of
fractionated irradiation, in the irradiation break pO2-measure-
ments were performed.
Photodynamic therapy
For light irradiation the animals wearing a transparent dorsal
skinfold chamber were immobilised in a Perspex tube. The animals
were randomly assigned to the different groups according to the
different protocols: control (I); high-dose PDT (100mWcm
 2,
100Jcm
 2), continuous irradiation (II); high-dose PDT
(100mWcm
 2, 100Jcm
 2), fractionated irradiation (III); low-
dose PDT (25mWcm
 2, 100Jcm
 2), continuous irradiation (IV);
low-dose PDT (25mWcm
 2, 100Jcm
 2), fractionated irradiation
(V). At the time of highest fluorescence intensity, 150min after
intravenous ALA application (500mgkg
 1 b.w), the irradiation
was performed with an incoherent light source (lem¼580–
740nm, PDT 1200, Waldmann, Germany) as published previously
(Abels et al, 1994, 1997a; Szeimies et al, 1995). The light dose of
100Jcm
–2 was kept constant in all groups. Following the
fractionated irradiation, the light was paused after a light dose of
20Jcm
–2for a break of 15min before the remaining 80Jcm
–2was
applied. The total duration of PDT light treatment was 16.6min
using high-PDT-dose rates (100mWcm
 2; 100Jcm
 2), respec-
tively and 66.6min using low-PDT-dose rates (25mWcm
 2;
100Jcm
 2).
The animals bearing a solid subcutaneous tumour were placed
in a Perspex tube for light treatment. The distance between the
animal body and the tumour was increased by raising a skin flap
bearing the tumour through a slit in the Perspex tube and fixing it
along a plastic arch with three sutures. At 150min after
intravenous ALA application, irradiation was performed with the
incoherent light source. The animals were again assigned to the
different groups according to the protocol. In addition, a group
with continuous irradiation (25mWcm
 2, 100Jcm
 2) but without
ALA and a control group were performed. The tumour volume was
measured throughout the complete observation period (28days).
The longer (l) and the shorter (w) perpendicular axes and the
height (h) of each tumour were measured with callipers prior to
and after PDT at 2–3-day intervals over 28 days. Individual
tumour volume was calculated using the formula Clwh, where C is
an empirically determined correction factor of 0.873 (Tomayko
and Reynolds, 1989; Weiss et al, 1990). Tumour response to PDT
was classified as follows: complete remission (disappearance of all
signs of tumour), partial remission (more than 50% decrease of the
product of the two largest perpendicular tumour diameters for a
minimum of 7 days), no changes (less than 50% decrease or less
than 25% increase of the product of the two largest perpendicular
tumour diameters for a minimum of 5days or progression (more
than 25% increase of the product of the two largest perpendicular
tumour diameters) (Livingston and Carter, 1982).
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sStatistics
For the graphics and statistical analysis of the data, ORIGIN
s
(Microcal, Northampton, MA, USA) or SigmaStat
s was used.
Results are expressed as the mean7standard error of the mean if
not indicated otherwise. Differences were considered as significant
if Po0.05.
RESULTS
pO2 measurements
Figure 1 shows oxygen maps of the dorsal skinfold chamber with
an amelanotic melanoma prior to and after PDT (100mWcm
 2,
100Jcm
 2, continuous irradiation) over the time (prior to, 30min,
2 and 24h after PDT). The maps are pseudocolour images, the
respective bar is inserted. Prior to PDT, the tumour region can be
clearly differentiated from normal tissue because of the lower pO2
giving in blue colours. The pO2 is reduced after irradiation in
tumour and surrounding tissue.
High-dose PDT
Figure 2 shows the pO2-measurements following high-dose PDT
(100mWcm
 2, 100Jcm
 2) irradiated either continuously
(Figure 2A) or fractionated (Figure 2B).
Continuous irradiation induced a significant decrease of pO2 at
any time in surrounding tissue and in tumour tissue: following
PDT, pO2 decreased from 25.576.1mmHg (baseline) to 11.273.3
mmHg (30min) followed by a slight increase to 1474.5mmHg
(24h) in surrounding tissue. In tumour tissue, pO2 decreased from
12.776.4mmHg (baseline) to 7.673.2mmHg (30min) to remain
at this level up to 24h (Figure 2A).
The fractionated irradiation induced a decrease of pO2 in
surrounding tissue and in tumour tissue as well (Figure 2B).
Following PDT, pO2 decreased from 22.273.7mmHg (baseline) to
18.274.3mmHg (in the irradiation break), to 11.074.8mmHg
(15min) and to 7.373.2mmHg (2h) followed by a slight increase
to 8.372.4mmHg (24h) in surrounding tissue. In tumour tissue,
pO2 decreased from 8.271.7mmHg (baseline) to 6.372.2mmHg
(in the irradiation break), and to 4.071.1mmHg (2h) followed by
a slight increase to 5.471.8mmHg (24h) (Figure 2B).
In surrounding tissue, there was a difference detectable
following high-dose PDT with continuous irradiation as compared
to high-dose PDT with fractionated irradiation. The pO2 recovered
24h following irradiation to 55% of the baseline-value in
surrounding tissue following continuous irradiation, whereas
following fractionated irradiation, the pO2 showed just a slight
increase to 37% of the baseline-value 24h following irradiation
(Figure 2). In tumour tissue pO2 showed no significant difference
following continuous or fractionated irradiation as the pO2
recovered 24h following irradiation to 61% and to 66%,
respectively, of the baseline-value (Figure 2).
Low-dose PDT
Figure 3 shows the pO2-measurements following low-dose PDT
(25mWcm
 2, 100Jcm
 2) irradiated either continuously
(Figure 3A) or fractionated (Figure 3B).
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Figure 1 Oxygen maps of the dorsal skinfold chamber with A-Mel-3 tumour prior to and after PDT (100mWcm
 2, 100Jcm
 2, continuous irradiation)
over the time (prior to, 30min, 2h and 24h after PDT). The maps are pseudocolour images, the colour bar gives information regarding the colour–pO2
relation. Prior to PDT, the tumour region can be clearly differentiated from normal tissue because of its blue colour due to the lower oxygen tension. The
pO2 is reduced after irradiation in tumour and surrounding tissue.
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Figure 2 pO2 was measured prior to and 15min, 1h (30min), 2h and
24h (if fractionated additionally in the light pause) after high-dose PDT
(100mWcm
 2, 100Jcm
 2) in tumour tissue (’) and in surrounding
tissue (&) after continuous (A, n¼7) or fractionated (B, n¼6) irradiation.
A decrease of pO2 in tumour and surrounding tissue is shown following
high-dose PDT (median7s.e.m.).
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pO2 in surrounding tissue and in tumour tissue: following PDT,
pO2 decreased from 22.773.3mmHg (baseline) to 19.578.8
mmHg (15min), followed by a slight increase to 20.876.8mmHg
(1h) and to 25.676.8mmHg (2h), followed by a decrease to
1873.8mmHg (24h) in surrounding tissue. The slight increase of
tissue pO2 in surrounding tissue 2h after treatment is because of a
hyperaemic reaction. In tumour tissue, pO2 decreased from
6.671.9mmHg (baseline) to 4.072.0mmHg (15min), followed
by an increase after 2h, followed by a decrease to 5.270.9mmHg
(24h) (Figure 3A).
The fractionated irradiation induced a slight decrease of pO2 in
surrounding tissue and in tumour tissue as well (Figure 3B).
Following PDT, pO2 increased from 21.572.7mmHg (baseline) to
23.873.2mmHg (in the irradiation break), decreased to
17.776.7mmHg (15min/2h) followed by a slight decrease after
24h in surrounding tissue. In tumour tissue, pO2 increased from
7.071.5mmHg (baseline) to 12.372.2mmHg (in the irradiation
break), followed by a decrease to 7.672.6mmHg (15min) and to
6.371.9mmHg (1h), followed by a slight increase to 6.671.9
mmHg (2h), followed by a slight decrease to 5.471.6mmHg (24h)
(Figure 3B).
Remarkable is the fact that the pO2 in the irradiation break
increased in tumour and surrounding tissue following fractionated
low-dose PDT. On the contrary, following high-dose PDT, the pO2
decreased in the irradiation break in tumour and surrounding
tissue (Figures 2B and 3B).
Tumour growth curves
Figure 4 shows the tumour growth curves of the different
experimental groups. Prior to PDT, there was no statistical
difference of the tumour volume of any of the experimental
groups including the control group (I–VI) (Figure 4). Prior to
high-dose PDT (100mWcm
 2, 100Jcm
 2, groups II and III), the
mean volume of the subcutaneously grown tumours was
101716mm
3 in group II and 11376mm
3 in group III. Group II,
treated with continuous high-dose PDT, as well as group III,
treated with fractionated high-dose PDT, showed no signs of
tumour 3 days after therapy, instead a massive scar formation
developed. There was no recurrence up to the end of the
observation period. Thus, high-dose PDT induced complete
remission of all tumours (13 out of 13) (Table 1). Irradiation
either continuous or fractionated did not change the therapeutic
outcome in these groups (Figure 4).
Prior to low-dose PDT (25mWcm
 2, 100Jcm
 2, groups IV and
V), the mean volume of the subcutaneously grown tumours was
9775mm
3 in group IV and 10177mm
3 in group V. Group IV,
treated with continuous low-dose PDT, as well as group V, treated
with fractionated low-dose PDT, showed a reduced mean tumour
volume at day 3 (group IV: 10276mm
3; group V: 10878mm
3)
and day 5 (group IV: 161727mm
3; group V: 143716mm
3)a s
compared to control group (I) (day 3: 123713mm
3; day 5:
254760mm
3). From day 9 up to the end of the observation period,
there was no difference in tumour growth between group IV or
group V and the control group (I) detectable (Figure 4). There was
no significant difference in tumour growth curves following either
continuous or fractionated irradiation (Figure 4). In contrast to
high-dose PDT, low-dose PDT resulted in progression of all
tumours (13 out of 13), independent of the irradiation protocol
(Table 1).
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Figure 3 pO2 was measured prior to and 15min, 1h, 2h and 24h (if
fractionated additionally in the light pause) after low-dose PDT
(25mWcm
 2, 100Jcm
 2) in tumour tissue (’) and in surrounding tissue
(&) after continuous (A, n¼7) or fractionated (B, n¼6) irradiation
(median7s.e.m.).
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Figure 4 A-Mel-3 amelanotic melanomas were implanted subcuta-
neously in the dorsal skinfold of Syrian Golden hamsters (n¼38). At
150min after i.v. ALA application (500mgkg
 1 b.w.) irradiation was
performed. Six groups were formed according to the protocols: (~)
control (I, n¼6); (b) high-dose PDT (100mWcm
 2, 100Jcm
 2),
continuous irradiation (II, n¼7); (’) high-dose PDT (100mWcm
 2,
100Jcm
 2), fractionated irradiation (III, n¼6); (K) low-dose PDT
(25mWcm
 2, 100Jcm
 2), continuous irradiation (IV, n¼7); (m) low-
dose PDT (25mWcm
 2, 100Jcm
 2), fractionated irradiation (V, n¼6);
(.) low-dose PDT (25mWcm
 2, 100Jcm
 2), continuous irradiation
without ALA (VI, n¼6)]. Tumour volumes were recorded throughout the
complete observation period (28 days) (median7s.e.m.).
ALA – PDT following different dosimetric protocols
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 2,
group VI), the mean volume of the subcutaneously grown tumours
was 92712.5mm
3. During the whole observation period, there was
no significant difference in tumour growth between group VI and
the control group (I) (Figure 4). The tumour growth curve showed
an exponential trend. Low-dose PDT without ALA resulted in
progression of all tumours (six out of six) (Table 1).
The subcutaneously grown tumours of the control group (I)
showed a mean tumour volume of 9473.4mm
3 at the beginning of
the observation period. The tumour growth curves showed an
exponential growth (Figure 4). All tumours showed progression
(six out of six) (Table 1).
DISCUSSION
This study shows that only high-dose PDT (100mWcm
 2;
100Jcm
 2) with ALA results in a significant decrease of pO2 24h
after PDT as compared to low-dose PDT (25mWcm
 2, 100Jcm
 2)
(Figures 2 and 3). Fractionation of PDT did not show any effect
regarding the pO2 in tumour tissue. However, following fractio-
nated irradiation, the pO2 in surrounding tissue decreased to a
significant lower value 24h after either high-dose or low-dose PDT
as compared to tumour tissue (Figures 2 and 3).
Only high-dose PDT induced complete remission of all tumours
(13 out of 13). Neither continuous nor fractionated irradiation did
change the therapeutic outcome after high-dose or low-dose PDT
(Figure 4).
The dorsal skinfold chamber model was used in the present
study because this tumour model is well established to investigate
the microcirculatory effects on tumour and normal tissue
following different therapeutic approaches (Dellian et al, 1995;
Schacht et al, 2001). In addition, measuring the tumour volume of
the subcutaneously implanted amelanotic melanoma after PDT has
been studied as well to evaluate the efficacy of different anticancer
treatments (Weiss et al, 1990; Szeimies et al, 1995; Dellian et al,
1996; Abels et al, 1997a,b).
Photodynamic therapy was performed according to previous
studies (Abels et al, 1994, 1997a; Szeimies et al, 1995). Since in the
literature it is reported that low-dose PDT or fractionated
irradiation may be more effective as compared to high-dose PDT
or continuous irradiation (Gibson et al, 1990; Messmann et al,
1995; de Bruijn et al, 1999; Iinuma et al, 1999), PDT dosimetry was
performed with a light intensity of either 100 or 25mWcm
 2 and
light was applied either continuously or fractionated according to
the experiments of Curnow et al (2000) and de Bruijn et al (1999).
The efficacy of ALA–PDT was evaluated by measuring the tissue
pO2 (Blumenroder et al, 1997; Hartmann et al, 1997; Curnow et al,
2000; Niedre et al, 2002) since tissue pO2 correlates with a functional
microcirculation (Vaupel, 1994). The technique of measuring the
tissue pO2 by luminescence lifetime imaging using planar oxygen
sensors allows a spatially highly resolved and time-resolved
mapping of two-dimensional pO2-distribution within the entire
chamber tissue in a noninvasive way (Liebsch et al, 2000, 2001).
Thus, two independent parameters to assess PDT efficacy were
determined: the tissue pO2 can be considered as a short-term
parameter (up to 24h after PDT), whereas the tumour growth
curves represent the long-term parameter (up to 28 days after PDT).
In Figure 2A and B, pO2 in tumour and surrounding tissue
decreases up to 24h following continuous or fractionated high-
dose PDT. This result is in agreement with the literature. McIlroy
et al (1998) described a 10-fold decrease of the oxygen level in
normal rat liver following PDT with ALA (100mW, 60J) (McIlroy
et al, 1998). The decline of pO2 following PDT could be caused by
photochemical consumption of molecular oxygen (Busch et al,
2000) or by the lack of oxygen supply caused by massive
microvascular damage following high-dose PDT (Castellani et al,
1963; Vaupel et al, 1977, 1981, 1989). The fragile microvasculature
of experimental and human solid tumours is characterised already
in very early growth stages by structural and functional
abnormalities (Vaupel et al, 1989). The structural abnormalities
can result in deficient endothelial lining or basement membrane,
in loss of vessel hierarchy or in heterogeneous vascularisation,
whereas the functional abnormalities can lead to an increased
vascular fragility, to an increase of viscous resistance with micro-
and macrothrombosis or to an increased interstitial fluid pressure
(Ribbert, 1904; Vaupel et al, 1989). These specific characteristics
make the microvasculature of experimental and human solid
tumours very vulnerable for any treatment targeting the micro-
vasculature, like PDT.
In contrast to other investigations, fractionation of the light dose
(20Jcm
 2, 15min, 80Jcm
 2) did not further decrease pO2 in
tumour tissue in the present study. However, in surrounding tissue
a further reduction of pO2 24h after PDT is shown (Figure 2B).
Curnow et al (2000) described using the polarographic Eppendorf
pO2 histograph system in three animals also a benefit of
fractionation (5J, 150s, 20J) of PDT with ALA (200mgkg
 1)i n
the normal rat colon. They measured a greater decrease of pO2 and
a greater area of necrosis following fractionated irradiation.
However, they did not perform any measurements in tumour
tissue. Despite the fact that the Eppendorf pO2 histograph is
considered to be the gold standard for measuring pO2 in tissue
(Nozue et al, 1996), it does not allow a spatially and highly time-
resolved measurement of the pO2-value as compared with the
method used in this study. Curnow et al were not able to accurately
ascertain in which tissue layer the polarographic Eppendorf needle
is located during measurements. Moreover, they did perform the
measurements only at one site per animal. According to the
extensive investigations by Vaupel (Vaupel et al, 1977, 1981, 1989)
measuring just at one point does not represent the entire tissue
(Lord and Paoni, 2001). Besides this, the mechanical pressure
exerted by placing the needle in the tissue can easily irritate the
membrane and therefore change the diffusion capacity of the
membrane. The used technique against the background of
measuring the pO2 just in normal tissue and not in tumour tissue
makes this study incomparable to the results of our study as
described above. Most probably if the study had focused on
tumour tissue they would have obtained similar results.
Table 1 Complete remission of all tumours induced by high-dose PDT
Groups ALA (mgkg
 1 b.w.) Light intensity (mWcm
 2) Irradiation Complete remission Partial remission No change Progression
I FF F 0/6 0/6 0/6 6/6
II 500 100 Continuous 7/7 0/7 0/7 0/7
III 500 100 Fractionated 6/6 0/6 0/6 0/6
IV 500 25 Continuous 0/7 0/7 0/7 7/7
V 500 25 Fractionated 0/6 0/6 0/6 6/6
VI F 25 Continuous 0/6 0/6 0/6 6/6
PDT¼photodynamic therapy. Data represent the therapeutic outcome after 28 days of a subcutaneously implanted amelanotic malignant melanoma (A-Mel-3) in Syrian Golden
hamsters following PDT with 5-ALA i.v. (500mgkg
 1 b.w.) and irradiation (fluence: 100Jcm
-2) 150min thereafter using incoherent light source and different dosimetric
parameters.
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R3230Ac mammary adenocarcinoma after fractionated PDT with
Verteporfin
s directly after completion of the irradiation a
heterogeneous reduction of tissue pO2, but not complete anoxia.
Unfortunately, measurements in surrounding normal tissue were
not taken. Nevertheless, using laser Doppler measurements in the
same experiments, a significant reduction of blood flow during the
initial phase of irradiation could be shown (Pogue et al, 2001).
Measuring the diameter of necrosis in tumour and normal tissue
following mTHPC-mediated PDT, Tsutsui et al (2002) showed a
significant enhancement of necrosis produced only in normal
tissue and not in tumour tissue following fractionated irradiation
with 100mW. This finding supports our result showing that if an
efficient PDT is performed, a fast breakdown of the microcircula-
tion in tumours occurs preventing an additional benefit of
fractionated irradiation in tumour tissue, but not in the
surrounding tissue with a less fragile microvascular system, which
is still functioning, thus supplying oxygen (Djavaheri-Mergny et al,
2001; Lord and Paoni, 2001).
Following low-dose PDT (25mWcm
 2,1 0 0 J c m
 2)a n dc o n t i n -
uous irradiation, a slight but not significant reduction of tissue pO2
can be observed 24h after treatment in this model (Figure 3A). Since
high-dose PDT with continuous irradiation resulted in 100%
complete remission (Figure 4), this dosimetry protocol, not
inducing complete remission, was chosen to demonstrate a benefit
by using fractionated irradiation. As expected, an increase of tissue
pO2 in surrounding tissue (111% of baseline) and an even more
pronounced increase in tumour tissue (176% of baseline) could be
measured during the irradiation break (Figure 3B). Nevertheless,
24h after irradiation there is a higher relative decrease of pO2 in
surrounding tissue (58.6% of baseline) as compared to tumour
tissue (77.1% of baseline). The increase of tissue pO2 in tumour and
surrounding tissue during the irradiation break can be explained by
a reduced cellular respiration break by functioning oxygen supply.
This assumption is supported by the fact that ALA is primarily
metabolised to porphyrins in the tumour parenchyma (Fritsch et al,
1997). Therefore, direct tumour cell toxicity by PDT with ALA is
expected. Further evidence is given by measurements of NADH
fluorescence to assess acute cellular PDT-induced damage in vivo,
showing a significant reduction directly after the first fraction of
irradiation using Verteporfin
s as photosensitiser (Pogue et al,
2001). Comparing continuous vs fractionated irradiation for low-
dose PDT, no difference can be measured regarding pO2 24h after
treatment in tumour tissue, but as for high-dose PDT only in the
surrounding tissue, difference can be measured.
The tumour growth curves (Figure 4) show a completely
different development comparing high-dose PDT (groups II and
III) with low-dose PDT (groups IV and V). There was no difference
following high-dose PDT regarding continuous or fractionated
irradiation, because continuous irradiation induced disappearance
of all signs of tumour 3 days after therapy. Thus, any benefit of
fractionated irradiation would have been masked. According to
previous results using this model (Szeimies et al, 1995; Abels et al,
1997), the development of the tumour growth curves after high-
dose PDT was unexpected, because in these experiments PDT
using the same parameters and continuous irradiation yielded only
one complete remission out of six subcutaneously implanted
amelanotic melanomas. The only experimental difference is the use
of an argon-pumped dye laser tuned to 635nm for irradiation,
while in the present investigation an incoherent light source
(l¼580–740nm) was employed. Since significant amounts of
additional porphyrins, besides PpIX, are formed in this model
following systemic application of ALA (Fritsch et al, 1997)
absorbing beyond 635nm; the wavelength range of the incoherent
light source covers their absorption spectrum, thus leading to a
more pronounced photodynamic effect.
In contrast, low-dose PDT with either continuous or fractio-
nated irradiation shows just a transient and small delay of tumour
growth at days 3–7 as compared to the control group (Figure 4).
Moreover, at day 5 there might be a nonsignificant difference
visible between continuous (162727mm
3) or fractionated irradia-
tion (143717mm
3), showing the influence of the significant
reduction of pO2 in the surrounding tissue after 24h by
fractionated low-dose PDT (Figure 3B).
These results regarding the efficacy of low-dose vs high-dose
PDT with ALA are supported by the findings of Iinuma et al
(1999), which could demonstrate a 2-log cell kill and a 3-log cell
kill for ALA–PDT with either 30 or 100mWcm
 2, respectively, in
a rat tumour model in vivo.
In contrast, Tsutsui et al (2002) found a low-dose PDT to be
more effective by measuring the depth of necrosis in tumour tissue
following mTHPC-mediated PDT. They documented that depth of
necrosis following continuous PDT with a low light intensity
(5mW) is significantly larger as compared to PDT with a high light
intensity (100mW) from 2.5 to 30J total light energy. However,
they did not perform an irradiation with a high light dose of
100Jcm
 2 as carried out in this study.
A 100% complete remission (13 out of 13) was achieved
following high-dose PDT (100mWcm
 2, 100Jcm
 2) (Table 1).
Both irradiation schemes, continuous and fractionated, turned out
to be exactly equivalent concerning the therapeutic efficacy in this
model. In contrast, no complete remission was observed after low-
dose PDT and this is also independent of the irradiation scheme.
Therefore, these results do not support the hypothesis that lower
PDT fluence rates are associated with increased efficiency of
tumour response (Sitnik and Henderson, 1998). Surprisingly, in
this study no complete remission of the radiation induced fibro
sarcoma (RIF) tumour was obtained using Photofrin
s (5mgkg
 1)
and high-dose PDT (150mWcm
 2, 100Jcm
 2), whereas in our
model using these parameters and Photofrin
s in five out of six
tumours a complete remission is achieved (Dellian et al, 1996).
In conclusion, measuring tissue pO2 by means of luminescence
lifetime imaging proves to be a helpful tool to evaluate the acute
effects of PDT on the microcirculation. Only high-dose PDT with a
high light intensity and a high light dose induces complete
remission in our model. Moreover, it could be shown that
fractionating the light dose enhances the effect of PDT only in
surrounding but not in tumour tissue, since oxygen supply in
tumour tissue is already maximal because of the characteristic
structural and functional abnormalities of the tumour micro-
vasculature. In addition, no significant effect of fractionated
irradiation was shown in our tumour model regarding the
therapeutic efficacy 28 days after PDT. The pO2-measurements
correlate with the measurements of the tumour volume, only PDT
inducing a significant reduction of pO2 in tumour as well as
normal tissue 24h after PDT resulted in complete remission of
tumours 28 days after PDT.
Thus, performing a fractionated PDT with ALA or reducing the
light intensity and increasing irradiation time seems not successful
in clinical PDT according to the present data.
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